Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience

Siobhan C. McKay (Lead / Corresponding author), Samir Pathak, Richard J.W. Wilkin, Sivesh K. Kamarajah, Stephen J. Wigmore, Jonathan Rees, Declan F.J. Dunne, Giuseppe Garcea, Jawad Ahmad, Nicola de Liguori Carino, Asma Sultana, Mike Silva, Pavlos Lykoudis, David Nasralla, James Milburn, Nehal Shah, Hemant M. Kocher, Ricky Bhogal, Ryan D. Baron, Alex NavarroJames Halle-Smith, Bilal Al-Sarireh, Gourab Sen, Nigel B. Jamieson, Christopher Briggs, David Stell, Somaiah Aroori, Matthew Bowles, Aditya Kanwar, Simon Harper, Krishna Menon, Andreas Prachalias, Parthi Srinivasan, Adam E. Frampton, Claire Jones, Ali Arshad, Iain Tait, Duncan Spalding, Alastair L. Young, Damien Durkin, Manijeh Ghods-Ghorbani, Robert P. Sutcliffe, Keith J. Roberts

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The SARS-CoV-2 pandemic presented healthcare providers with an extreme challenge to provide cancer services. The impact upon the diagnostic and treatment capacity to treat pancreatic cancer is unclear. This study aimed to identify national variation in treatment pathways during the pandemic.

Methods: A survey was distributed to all United Kingdom pancreatic specialist centres, to assess diagnostic, therapeutic and interventional services availability, and alterations in treatment pathways. A repeating methodology enabled assessment over time as the pandemic evolved.

Results: Responses were received from all 29 centres. Over the first six weeks of the pandemic, less than a quarter of centres had normal availability of diagnostic pathways and a fifth of centres had no capacity whatsoever to undertake surgery. As the pandemic progressed services have gradually improved though most centres remain constrained to some degree. One third of centres changed their standard resectable pathway from surgery-first to neoadjuvant chemotherapy. Elderly patients, and those with COPD were less likely to be offered treatment during the pandemic.

Conclusion: The COVID-19 pandemic has affected the capacity of the NHS to provide diagnostic and staging investigations for pancreatic cancer. The impact of revised treatment pathways has yet to be realised.

Original languageEnglish
Number of pages10
JournalHPB
Early online date19 Mar 2021
DOIs
Publication statusE-pub ahead of print - 19 Mar 2021

Fingerprint

Dive into the research topics of 'Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience'. Together they form a unique fingerprint.

Cite this